PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'CPC Clinical Research, Aurora, CO; Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO. Electronic address: warren.capell@cuanschutz.edu.\', \'Janssen Research and Development LLC, Raritan, NJ.\', \'Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women\'s Hospital, Harvard Medical School, Boston, MA.\', \'Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Huntington, NY; Institute for Health Innovation and Outcomes Research, Feinstein Institutes for Medical Research, Manhasset, NY; Department of Medicine, Northwell Health at Lenox Hill Hospital, New York, NY.\', \'CPC Clinical Research, Aurora, CO; Division of Cardiology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.\', \'REDCap Cloud, Encinitas, CA.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S0002-8703(21)00033-810.1016/j.ahj.2021.02.001
?:hasPublicationType
?:journal
  • American heart journal
is ?:pmid of
?:pmid
?:pmid
  • 33577800
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 3.267
?:rankingScore_hIndex
  • 169
is ?:relation_isRelatedTo_publication of
?:title
  • Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33577800>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33577800>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all